Condition: Cardiac Surgery · Sponsor: Quark Pharmaceuticals
This trial is designed to evaluate QPI-1002 versus placebo for the prevention of Major Adverse Kidney Events (MAKE) in subjects at high risk for acute kidney injury following cardiac surgery. Half of the participants will receive QPI-1002 while the other half will receive placebo.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Hospital | Birmingham, Alabama, United States | — |
| Keck Hospital of USC | Los Angeles, California, United States | — |
| Cedar-Sinai Heart Institute | Los Angeles, California, United States | — |
| Ronald Regan UCLA Medical Center | Los Angeles, California, United States | — |
| Yale University School of Medicine | New Haven, Connecticut, United States | — |
| River City Clinical Research | Jacksonville, Florida, United States | — |
| Jacksonville Center for Clinical Research | Jacksonville, Florida, United States | — |
| Emory Saint Joseph's Hospital | Atlanta, Georgia, United States | — |
| Northwestern University | Evanston, Illinois, United States | — |
| Indiana/ Ohio Heart, a division of Luthern Medical Group, LLC | Fort Wayne, Indiana, United States | — |
| Indiana University Health-Methodist Hospital | Indianapolis, Indiana, United States | — |
| University of Kentucky Healthcare | Lexington, Kentucky, United States | — |
+ 92 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03510897